The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells
Open accessAbstract
Background Cancer immunotherapy involving NK-cell infusions and administration of therapeutic agents modulating the susceptibility of tumors to NK-cell lysis has been recently proposed. Here we provide a method to expand highly cytotoxic clinical grade NK cells in vitro for adoptive transfer following bortezomib treatment in patients with advanced malignancies. Methods NK cells were expanded with irradiated Epstein-Barr virus-transformed lymphoblastoid cells. Expanded cells were evaluated for their phenotype, cytotoxicity, cytokine secretion, dependence on IL-2 and the ability to retain function after cryopreservation. Results A pure population of clinical grade NK cells expanded 490±260 fold over 21 days. Expanded NK cells had increased TRAIL, FasL, and NKG2D expression and significantly higher cytotoxicity against bortezomib-treated tumors compared with resting NK cells. Expanded NK cells, co-cultured with K562 and renal cell carcinoma tumor targets, secreted significantly higher levels of sFasL, IFNγ, GM-CSF, TNFα, MIP-1α, and MIP-1β compared with resting NK cells. Secretion of the above cytokines and NK-cell cytolytic function were IL-2 dose dependent. Cryopreservation of expanded NK cells reduced expression of NKG2D and TRAIL and NK-cell cytotoxicity, though this effect could be reversed by exposure of NK cells to IL-2. Discussion Here we show a method for the large scale expansion of NK cells with increased expression of activating receptors and death receptor ligands resulting in superior cytotoxicity against tumor cells. This ex vivo NK-cell expansion technique is currently being utilized in a clinical trial evaluating the anti-tumor activity of adoptively-infused NK cells in combination with bortezomib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Natural Killer Cells
Trinchieri, G. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60664-1 · Cited by 2,902
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Biology and clinical relevance of human natural killer cells
Robertson, M., & Ritz, J. (1990) · Blood · doi:10.1182/blood.v76.12.2421.2421 · Cited by 931
Imai, C., Iwamoto, S., & Campana, D. (2005) · Blood · doi:10.1182/blood-2004-12-4797 · Cited by 659
Cutting Edge: Immune Cells as Sources and Targets of the IL-10 Family Members?
Wolk, K., Kunz, S., Asadullah, K., & Sabat, R. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5397 · Cited by 583
Prospects for the use of NK cells in immunotherapy of human cancer
Ljunggren, H.-G., & Malmberg, K.-J. (2007) · Nature Reviews Immunology · doi:10.1038/nri2073 · Cited by 543
Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect
Farag, S. S., Fehniger, T. A., Ruggeri, L., Velardi, A., & Caligiuri, M. A. (2002) · Blood · doi:10.1182/blood-2002-02-0350 · Cited by 491
Cooper, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.10.012 · Cited by 434
Perussia, B., Trinchieri, G., Jackson, A., Warner, N. L., Faust, J., Rumpold, H., Kraft, D., & Lanier, L. L. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.1.180 · Cited by 328
Sayers, T. J., Brooks, A. D., Koh, C. Y., Ma, W., Seki, N., Raziuddin, A., Blazar, B. R., Zhang, X., Elliott, P. J., & Murphy, W. J. (2003) · Blood · doi:10.1182/blood-2002-09-2975 · Cited by 227
Cited by
NK cells for cancer immunotherapy
Shimasaki, N., Jain, A., & Campana, D. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0052-1 · Cited by 1,222
CAR-NK cells: A promising cellular immunotherapy for cancer
Xie, G., Dong, H., Liang, Y., Ham, J. D., Rizwan, R., & Chen, J. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102975 · Cited by 800
“[25] Co-culturing with stimulatory cells, such as a Wilms tumour-derived cell line, [78] autologous PBMCs, [79,80] Epstein-Barr virus-transformed lymphoblastoid cells, [81,82] and chronic myelogenous leukaemia-derived cell line K562 cells, [83] can induce rapid and sustained proliferation in NK cells.”
BackgroundMembrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Denman, C. J., Senyukov, V. V., Somanchi, S. S., Phatarpekar, P. V., Kopp, L. M., Johnson, J. L., Singh, H., Hurton, L., Maiti, S. N., Huls, M. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030264 · Cited by 683
Mamessier, E., Sylvain, A., Thibult, M.-L., Houvenaeghel, G., Jacquemier, J., Castellano, R., Gonçalves, A., André, P., Romagné, F., Thibault, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45816 · Cited by 681
NK cell-based immunotherapy for malignant diseases
Cheng, M., Chen, Y., Xiao, W., Sun, R., & Tian, Z. (2013) · Cellular & Molecular Immunology · doi:10.1038/cmi.2013.10 · Cited by 631
Metadata
- Authors
- Berg, M., Lundqvist, A., McCoy, P., Samsel, L., Fan, Y., Tawab, A., & Childs, R.
- Venue
- Cytotherapy
- Publisher
- Elsevier BV
- Published
- 2009
- Volume
- 11
- Issue
- 3
- Pages
- 341-355
- ISSN
- 1465-3249 (ISSN-L)
- OpenAlex
- W2070120246
- Cited by
- 304
- References
- 23
- FWCI
- 8.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. https://app.cochat.ai/papers/10.1080/14653240902807034
- The paper
- Berg, M., Lundqvist, A., McCoy, P., Samsel, L., Fan, Y., Tawab, A., & Childs, R. (2009). Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy. https://doi.org/10.1080/14653240902807034
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.